Even in the context of antigen loss, dual-targeting CAR T cells can retain anti-tumor activity in cell lines and in a plasma cell tumor from a patient who relapsed after BCMA-targeted CAR T cell therapy. This evidence concerns the gene TNFRSF17 and neoplasm.